


NEW SYNTHESIS OF KT5823 INDOLOCARBAZOLE AGLYCONE

Guillaume E. Burtin,* David J. Madge* and David L. Selwood


The Wolfson Institute for Biomedical Research, Biological and Medicinal Chemistry,
University College London, Cruciform Building, Gower St., London WC1E 6AU, UK.

Abstract - The indolo[2,3-*a*]pyrrolo[3,4-*c*]carbazole aglycone of the selective protein kinase G inhibitor KT5823 has been synthesised in four steps and 36% overall yield from 2,3-dichloro-*N*-methylmaleimide by utilising an efficient new two step reduction sequence for the key imide to amide transformation.


In 1977 the first indolocarbazole alkaloid, staurosporine (**1**) was isolated from *Streptomyces staurosporeus*.¹ Since then, the number of isolated and synthesised indolocarbazole glycosides has grown considerably due to their wide range of biological properties, from antifungal, antimicrobial, and antitumor through to antihypertensive effects.² Synthetic chemists have concentrated their efforts on the synthesis of the naturally occurring indolocarbazole K252c (**2**) and several strategies have been reported.³




(1) : staurosporine



(2) : K252c (R = H)
(5) : KT5823 aglycone (R = Me)



(3) : arcylriaflavin A




(4) : KT5823

For many years, the most widely used approaches to the aglycone (**2**) had involved the imide arcylriaflavin A (**3**) as a key intermediate, although its reduction to the lactam (**2**) proved to be difficult.⁴ Several groups have recently developed new synthetic pathways to give direct access to analogues of **2**.⁵

As part of a program investigating the biological activity of (\pm)-KT5823 (**4**) towards the inhibition of protein kinase G,⁶ we report here an efficient and high yielding synthesis of the KT5823 indolo[2,3-*a*]pyrrolo[3,4-*c*]carbazole aglycone (**5**). Only one synthesis of lactam (**5**) has been described to date, with no experimental detail and in poor yield.⁷ The strategy involving the *bis*-indolylmaleimide (**7**) was considered as the most convenient route to prepare large quantities of aglycone (**5**) (Scheme 1).⁸

Treatment of 2,3-dichloro-*N*-methylmaleimide⁹ (**6**) with indole in presence of ethylmagnesium bromide afforded intermediate (**7**).¹⁰ In our hands, the utilisation of 3 equivalents of indole-MgBr gave higher yields. Oxidative cyclisation of the *bis*-indolylmaleimide (**7**) with a large excess of palladium chloride (5 eq.) in dimethylformamide provided product (**8**) in good yield.¹¹ The use of a 2:1 mixture of toluene and dimethylformamide allowed the reaction to go to completion with only 3.5 equivalents of expensive PdCl₂. Cyclisation using palladium acetate in acetic acid¹² gave poor results and CuCl₂ in methyl ethyl ketone¹³ failed to provide the imide (**8**). The product obtained with DDQ/TsOH¹⁴ proved to be difficult to purify.




Scheme 1. (a) EtMgBr, toluene/THF, 90°C; 80%; (b) PdCl₂, toluene/DMF, 105°C, 90%.

Final reduction of imide (**8**) to lactam (**5**) required more attention. Although Clemmensen type reduction of arcyriaflavin A (**3**) has been carried out by several groups to prepare K252c (**2**),^{4,15} treatment of (**8**) with acid activated zinc¹⁶ in place of toxic zinc-amalgam gave the lactam (**5**) in poor yield. The use of BH₃.THF complex gave a mixture of reduced compounds.¹⁷ The two step reduction sequence developed by Hill *et al.*¹² and used by Somei *et al.*⁷ in the synthesis of aglycone (**2**) gave rise to the unexpected ethoxyindolocarbazole (**11**)¹⁸ (Scheme 2). We assume that compound **11** results from the addition of ethanol to the iminium species (**10**).


Formation of **10**, which presumably occurs by elimination of the hydroxyl from intermediate (**9**) due to the participation of indolic nitrogen, was also observed during attempts to purify crude **9** on silica gel

using a methanol-chloroform gradient. In this case partial elimination, followed by addition of methanol to **10**, led to a mixture of the alcohol (**9**) and the methoxy analogue of **11**. Although hydrogenolysis of compound **9** in ethyl acetate failed to give **5**, the use of ethanol-acetic acid afforded a separable mixture of **5** and **11**.



Scheme 2. (a) NaBH₄, DMF/MeOH; (b) 10% Pd/C, H₂, EtOH, rt, 42% two steps

Efficient reduction of imide (**8**) was finally achieved using the two step sequence shown in Scheme 3. Reduction of **8** with an excess of lithium aluminium hydride at room temperature yielded hydroxy derivative (**9**). Treatment of crude hydroxy lactam (**9**) with a mixture of trifluoroacetic acid and triethylsilane^{19,15b} at room temperature led to the KT5823 aglycone (**5**)¹⁸ in 50% yield from **8**. Utilisation of toxic phenylselenol as a reducing agent of the hydroxy lactam has been avoided.³



Scheme 3. (a) LiAlH₄, THF, rt; (b) Et₃SiH, TFA, chloroform, rt, 50% two steps.

In summary, we have developed a new two step reduction sequence of indolopyrrolocarbazole giving access to the KT5823 aglycone (**5**) in four steps and 36% overall yield from *N*-methyl dichloromaleimide.

ACKNOWLEDGMENTS

This work was supported in part by *United Therapeutics Corp.* (Silver Spring, USA).

REFERENCES

- * Corresponding author. Tel: (0044) 207 6796712; Fax: (0044) 207 6796799; e-mail: d.madge@ucl.ac.uk
1. (a) S. Omura, Y. Iwai, A. Hirano, A. Nakagawa, J. Awaya, H. Tsuchiya, Y. Takahashi, and R. Masuma, *J. Antibiot.*, 1977, **30**, 275. (b) A. Furusaki, N. Hashiba, T. Matsumoto, A. Hirano, Y. Iwai, and S. Omura, *J. Chem. Soc., Chem. Commun.*, 1978, 800.
 2. For a review see G. W. Gribble and S. J. Berthel, 'Studies in Natural Products Chemistry', Vol. 12, ed. by Atta-ur-Rahman, Elsevier Science Publisher, New York, 1993, pp. 365-409.
 3. For a short survey of the different strategies see: J. T. Link, S. Raghavan, M. Gallant, S. J. Danishefsky, T. C. Chou, and L. M. Ballas, *J. Am. Chem. Soc.*, 1996, **118**, 2825.
 4. G. Xie and J. W. Lown, *Tetrahedron Lett.*, 1994, **35**, 5555.
 5. (a) S. Mahboobi, E. Eibler, M. Koller, S. Sumar, and A. Popp, *J. Org. Chem.*, 1999, **64**, 4697; (b) Y. Kobayashi, T. Fujimoto, and T. Fukuyama, *J. Am. Chem. Soc.*, 1999, **121**, 6501; (c) S. Eils and E. Winterfeldt, *Synthesis*, 1999, 275; (d) J. L. Wood, D. T. Petsch, B. M. Stoltz, E. M. Hawkins, D. Elbaum, and D. R. Stover, *Synthesis*, 1999, 1529.
 6. H. Kase, K. Iwahashi, S. Nakanishi, Y. Matsuda, K. Yamada, M. Takahashi, C. Murakata, A. Sato, and M. Kaneko, *Biochem. Biophys. Res. Commun.*, 1987, **142**, 436.
 7. M. Somei, H. Hayashi, T. Izumi, and S. Ohmoto, *Heterocycles*, 1995, **41**, 2161.
 8. M. Brenner, H. Rexhausen, B. Steffan, and W. Steglich, *Tetrahedron*, 1988, **44**, 2887.
 9. **6** was prepared in 60% yield using an adaptation of H. M. Relles, *J. Org. Chem.*, 1972, **37**, 3630.
 10. M. M. Faul, K. A. Sullivan, and L. L. Winneroski, *Synthesis*, 1995, 1511.
 11. M. Ohkubo, T. Nishimura, H. Jona, T. Honma, and H. Morishima, *Tetrahedron*, 1996, **52**, 8099.
 12. W. Harris, C. H. Hill, E. Keech, and P. Malsher, *Tetrahedron Lett.*, 1993, **34**, 8361.
 13. (a) M. Ohkubo, T. Nishimura, H. Jona, T. Honma, S. Ito, and H. Morishima, *Tetrahedron*, 1997, **53**, 5937; (b) M. Ohkubo, T. Nishimura, T. Honma, I. Nishimura, S. Ito, T. Yoshinari, H. Arakawa, H. Suda, H. Morishima, and S. Nishimura, *Bioorg. Med. Chem. Lett.*, 1999, **9**, 3307.
 14. R. P. Joyce, J. A. Gainor, and S. M. Weinreb, *J. Org. Chem.*, 1987, **52**, 1177.
 15. (a) D. Toullec, P. Pianetti, H. Coste, P. Bellevergue, T. Grand-Perret, M. Ajakane, V. Baudet, P. Boissin, E. Boursier, F. Loriolle, L. Duhamel, D. Charon, and J. Kirilovsky, *J. Biol. Chem.*, 1991, **266**, 15771; (b) I. Hughes, W. P. Nolan, and R. A. Raphael, *J. Chem. Soc., Perkin Trans I*, 1990, 2475.
 16. S. Yamamura, M. Toda, and Y. Hirata, *Org. Synth., Coll. Vol.*, 1988, **6**, 289.
 17. S. W. McCombie, R. W. Bishop, D. Carr, E. Dobek, M. P. Kirkup, P. Kirschmeier, S.-I. Lin, J. Petrin, K. Rosinski, B. B. Shankar, and O. Wilson, *Bioorg. Med. Chem. Lett.*, 1993, **3**, 1537.
 18. All new compounds gave satisfactory analytical and spectral data. *Compound (11)*: ^1H NMR (DMSO- d_6 , 400 MHz) δ 11.53 (NH), 11.39 (NH), 9.17 (d, $J = 7.9$ Hz, 1H), 8.31 (d, $J = 7.3$ Hz, 1H), 7.77 (d, $J = 8.1$ Hz, 1H), 7.74 (d, $J = 8.1$ Hz, 1H), 7.46 (q, $J = 7.8$ Hz, 2H), 7.30 (t, $J = 7.5$ Hz, 1H), 7.25 (t, $J = 7.7$ Hz, 1H), 6.62 (s, 1H, CHOEt), 3.19-3.11 (m, 1H, CH_2CH_3), 3.11 (s, 3H, Me), 2.86-2.82 (m, 1H, CH_2CH_3), 0.97 (t, $J = 7.0$ Hz, 3H, CH_2CH_3); ^{13}C NMR (DMSO- d_6 , 100 MHz) δ 168.6 (C=O), 139.6, 139.4, 129.0, 127.9, 126.4, 125.4, 124.8, 122.4, 122.0, 119.9, 119.2, 118.9, 115.2, 114.8, 111.8, 111.5, 87.3 (CHOEt), 56.4 (CH_2CH_3), 26.4 (Me), 15.1 (CH_2CH_3); Anal. Calcd for $\text{C}_{23}\text{H}_{20}\text{N}_3\text{O}_2$: C, 74.56; H, 5.45; N, 11.35. Found: C, 74.37; H, 5.68; N, 11.07. *Compound 5*: ^1H NMR (DMSO- d_6 , 400 MHz) δ 11.46 (NH), 11.30 (NH), 9.23 (d, $J = 8.0$ Hz, 1H), 8.02 (d, $J = 7.8$ Hz, 1H), 7.78 (d, $J = 8.3$ Hz, 1H), 7.72 (d, $J = 8.1$ Hz, 1H), 7.47 (t, $J = 7.7$ Hz, 1H), 7.42 (t, $J = 7.7$ Hz, 1H), 7.30 (t, $J = 7.5$ Hz, 1H), 7.22 (t, $J = 7.4$ Hz, 1H), 5.02 (s, 2H, CH_2), 3.25 (s, 3H, Me); ^{13}C NMR (DMSO- d_6 , 100 MHz) δ 169.5 (C=O), 139.3, 139.1, 130.0, 127.6, 125.4, 125.0, 122.8, 122.4, 120.9, 119.8, 118.9, 118.7, 115.4, 113.9, 111.9, 111.3, 51.6 (CH_2), 29.2 (Me); MS (APCI+) m/z : 326 (M+H); Anal. Calcd for $\text{C}_{21}\text{H}_{15}\text{N}_3\text{O} \cdot 0.7\text{H}_2\text{O}$: C, 74.62; H, 4.90; N, 12.43. Found: C, 74.82; H, 4.62; N, 12.22.
 19. D. Dube and A. A. Scolte, *Tetrahedron Lett.*, 1999, **40**, 2295 and references therein.